Astellas' XTANDI™ (Enzalutamide) Granted European Com

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) has approved a...

Related Keywords

Japan , Tokyo , Canada , United States , Barcelona , Comunidad Autonoma De Cataluna , Spain , American , America , Antonio Alcaraz , Ahsan Arozullah , European Union , Drug Administration , European Association Of Urology , European Commission , Department Of Urology , American Society Of Clinical Oncology , University Hospital Clinic Of Barcelona , Committee For Medicinal Products Human Use , European Medicines Agency , Astellas Pharma Inc , Prnewswire Astellas Pharma Inc , Head Of Oncology Development , European Association , University Hospital Clinic , Europa Uomo , Senior Vice President , Oncology Development , Medicinal Products , Human Use , Receives Positive , Medicines Agency Validates Type , Non Metastatic Hormone Sensitive Prostate Cancer , High Risk Biochemical , Pfizer Led Phase , South America , Important Safety Information , Product Characteristics , Focus Area Approach , Biochemically Recurrent Prostate , Clin Pract , Prostate Cancer ,